Display options
Cite
Pujari S, Srasuebkul P, Sungkanuparph S, et al. Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. J Antivir Antiretrovir. 2009;1(1):28-35doi: 10.4172/jaa.1000004.
Pujari, S., Srasuebkul, P., Sungkanuparph, S., Lim, P. L., Kumarasamy, N., Chuah, J., Kumar, R. N., Chen, Y. M., Oka, S., Choi, J. Y., Lee, M. P., Phanuphak, P., Kamarulzaman, A., Lee, C., Fujie, Z., Ditangco, R., Saphonn, V., Sirisanthana, T., Merati, T. P., Smith, J., & Law, M. G. (2009). Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. Journal of antivirals & antiretrovirals, 1(1), 28-35. https://doi.org/10.4172/jaa.1000004
Pujari, Sanjay, et al. "Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region." Journal of antivirals & antiretrovirals vol. 1,1 (2009): 28-35. doi: https://doi.org/10.4172/jaa.1000004
Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, Ditangco R, Saphonn V, Sirisanthana T, Merati TP, Smith J, Law MG. Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. J Antivir Antiretrovir. 2009 Nov 01;1(1):28-35. doi: 10.4172/jaa.1000004. PMID: 20505782; PMCID: PMC2875551.
Copy Download .nbib Format: NLM
Share it on

J Antivir Antiretrovir. 2009 Nov 01;1(1):28-35. doi: 10.4172/jaa.1000004.

Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region.

Journal of antivirals & antiretrovirals

Sanjay Pujari, Preeyaporn Srasuebkul, Somnuek Sungkanuparph, Poh Lian Lim, Nagalingeswaran Kumarasamy, John Chuah, Ritesh N Kumar, Yi-Ming A Chen, Shinichi Oka, Jun Yong Choi, Man-Po Lee, Praphan Phanuphak, Adeeba Kamarulzaman, Christopher Lee, Zhang Fujie, Rosanna Ditangco, Vonthanak Saphonn, Thira Sirisanthana, Tuti Parwati Merati, Jeff Smith, Matthew G Law

Affiliations

  1. Institute of Infectious diseases, Pune India.

PMID: 20505782 PMCID: PMC2875551 DOI: 10.4172/jaa.1000004

Abstract

OBJECTIVES: Regimens containing protease inhibitors (PI) are less commonly used in developing countries due to high cost and less availability. We evaluated characteristics of patients initiating PI-based therapy according to previous antiretroviral (ARV) exposure; factors associated with initiating a PI-containing regimen using newer versus older PIs, and proportion of patients with detectable viral loads (VL) after initiating a PI-based regimen. METHODS: This analysis includes all patients who have initiated a PI-based regimen. ARV exposure was categorised: naïve (no previous ARV), 1st, 2nd, >/= 3rd switches; a switch was defined as starting or stopping any drug in a regimen. Newer PIs were defined as those approved by the US FDA after 1 January 2000. Detectable VL at 12 months was defined as VL >/= 400 copies/mL. Characteristics at PI initiation were evaluated. Logistic regression was used to determine factors associated with initiating a newer PI and detectable VL at 12 months after PI initiation. RESULTS: 1106 patients initiated PI-based therapy; of these, 618 (56%) were naïve patients. Overall, 22% (176) of patients had detectable VL at 12 months following the PI initiation. Being from a high income country (vs. mid/low income, OR = 1.80, p = 0.034) were more likely to be associated with detectable VL. CONCLUSION: The use of PIs in this cohort is dictated by accessibility and affordability issues particularly for the newer PIs. Short-term virological outcomes following PI-therapy in our cohort were good, and were associated with CD4 count at time of initiation.

References

  1. Clin Infect Dis. 2007 Dec 1;45(11):1492-8 - PubMed
  2. AIDS. 2007 Mar 30;21(6):721-32 - PubMed
  3. AIDS. 2008 Jan 11;22(2):F1-9 - PubMed
  4. HIV Clin Trials. 2006 Sep-Oct;7(5):237-45 - PubMed
  5. AIDS. 2008 Jul 11;22(11):1305-12 - PubMed
  6. Mem Inst Oswaldo Cruz. 2007 Nov;102(7):785-92 - PubMed
  7. AIDS. 2008 Jan 2;22(1):75-82 - PubMed
  8. AIDS Res Hum Retroviruses. 2007 Oct;23(10):1303-8 - PubMed
  9. Antivir Ther. 2008;13(2):271-9 - PubMed
  10. AIDS Patient Care STDS. 2008 Jul;22(7):545-52 - PubMed
  11. AIDS Patient Care STDS. 2007 Dec;21(12):920-9 - PubMed
  12. Lancet. 2006 Aug 5;368(9534):466-75 - PubMed
  13. Clin Infect Dis. 2007 Feb 1;44(3):453-5 - PubMed
  14. J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):174-9 - PubMed
  15. Antivir Ther. 2003 Dec;8(6):603-9 - PubMed
  16. Drugs. 2008;68(1):43-72 - PubMed
  17. Clin Infect Dis. 2007 Feb 1;44(3):447-52 - PubMed
  18. AIDS. 2008 Jul 31;22(12):1389-97 - PubMed
  19. AIDS Res Hum Retroviruses. 2007 Oct;23(10):1223-9 - PubMed
  20. Clin Infect Dis. 2008 May 15;46(10):1589-97 - PubMed
  21. HIV Med. 2005 May;6(3):216-23 - PubMed
  22. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 - PubMed
  23. Antivir Ther. 2005;10(8):911-6 - PubMed
  24. Expert Opin Investig Drugs. 2007 May;16(5):735-41 - PubMed

Publication Types

Grant support